Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
VIR
Vir Biotechnology, Inc.
Vir is expanding a targeted oncology portfolio around masked T-cell engagers, placing it in Biotech - Oncology.
|
$841.83M |
$6.07
-2.10%
|
|
GERN
Geron Corporation
Geron directly develops and commercializes RYTELO (imetelstat), an oncology therapeutic indicated for lower-risk MDS.
|
$835.80M |
$1.30
|
|
JANX
Janux Therapeutics, Inc.
Company focuses on tumor-activated oncology therapies (TRACTr/TRACIr), placing JANX squarely in Biotech - Oncology.
|
$826.89M |
$13.76
+0.26%
|
|
VALN
Valneva SE
Valneva directly manufactures and sells vaccines (e.g., VLA15 Lyme vaccine, IXCHIQ chikungunya vaccine, IXIARO, DUKORAL) and is advancing multiple vaccine candidates, making vaccines its core product category.
|
$817.67M |
$10.03
-0.10%
|
|
KROS
Keros Therapeutics, Inc.
Duchenne muscular dystrophy (DMD) and associated cytopenias are rare diseases, aligning Keros Therapeutics' focused assets to Rare Diseases.
|
$766.01M |
$18.83
-2.23%
|
|
KE
Kimball Electronics, Inc.
Strategic expansion into Contract Manufacturing Organizations for medical devices aligns with KE's Medical CMO focus.
|
$746.66M |
$30.75
-2.01%
|
|
GYRE
Gyre Therapeutics, Inc.
Gyre Therapeutics develops and commercializes small-molecule therapeutics (lead Hydronidone/F351 and multiple pipeline agents, plus licensed products) for fibrotic diseases, which fits the 'Oral Small Molecule Therapeutics' category.
|
$739.69M |
$7.68
-0.26%
|
|
KURA
Kura Oncology, Inc.
Kura's core business is oncology-focused biotechnology developing ziftomenib and related menin inhibitors for AML, placing it in Biotech - Oncology.
|
$734.30M |
$8.46
-5.11%
|
|
IRWD
Ironwood Pharmaceuticals, Inc.
LINZESS is a peptide-based therapeutic, aligning with the Peptide Therapeutics investable theme.
|
$730.95M |
$4.49
-0.66%
|
|
KALV
KalVista Pharmaceuticals, Inc.
EKTERLY (sebetralstat) is KalVista's lead asset and is an oral small-molecule therapeutic for acute hereditary angioedema, directly reflecting their product category.
|
$729.32M |
$14.60
-2.44%
|
|
EMBC
Embecta Corp.
Embecta provides contract manufacturing/partner manufacturing services and potential co-packaging arrangements.
|
$724.63M |
$12.41
-1.51%
|
|
BIOA
BioAge Labs, Inc.
BioAge's lead program BGE-102 is an oral small-molecule therapeutic, and APJ agonists are being developed for obesity, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$722.74M |
$20.16
-6.28%
|
|
NKTR
Nektar Therapeutics
NKTR's core immunology focus with REZPEG and TNFR2 antibody programs aligns with Immunology Therapeutics.
|
$716.62M |
$37.65
+6.48%
|
|
ASPI
ASP Isotopes Inc. Common Stock
ASPI’s PET Labs Radiopharmaceuticals production and enriched isotopes are delivered as a core product line.
|
$711.41M |
$7.72
+3.21%
|
|
CMPS
COMPASS Pathways plc
Represents the company's focus on developing neuropsychiatric drugs in the CNS space.
|
$705.17M |
$7.34
+0.48%
|
|
ATXS
Astria Therapeutics, Inc.
Astria Therapeutics develops monoclonal antibody therapeutics (navenibart and STAR-0310).
|
$703.74M |
$12.48
-2.58%
|
|
RGNX
REGENXBIO Inc.
Core product category: gene therapy using NAV AAV platform.
|
$688.00M |
$13.64
-0.84%
|
|
RIGL
Rigel Pharmaceuticals, Inc.
Rigel's core products are oncology/hematology therapies (TAVALISSE, REZLIDHIA, GAVRETO), fitting Biotech - Oncology.
|
$672.29M |
$37.55
-0.61%
|
|
PROK
ProKidney Corp.
Core product is rilparencel (REACT), an autologous cell therapy for preserving kidney function in CKD, fitting the Biotech - Cell Therapy category.
|
$656.25M |
$2.23
-0.22%
|
|
CGEM
Cullinan Therapeutics, Inc.
Cullinan develops bispecific antibodies (CD19xCD3 and BCMAxCD3) as core assets.
|
$633.28M |
$10.73
+0.66%
|
|
DRUG
Bright Minds Biosciences Inc.
Directly relates to development of neuropsychiatric/CNS therapeutics targeting serotonin receptors.
|
$623.45M |
$88.00
-2.12%
|
|
IVA
Inventiva S.A.
Inventiva's lanifibranor is an orally administered small-molecule therapeutic for MASH, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$622.76M |
$6.51
+6.37%
|
|
SRDX
Surmodics, Inc.
The company provides proprietary drug-delivery platform technologies used on medical devices (SurVeil DCB) and related platforms.
|
$614.58M |
$42.98
|
|
ESPR
Esperion Therapeutics, Inc.
Directly sells/markets cardiovascular drugs (NEXLETOL, NEXLIZET).
|
$612.93M |
$3.04
-2.88%
|
|
MGTX
MeiraGTx Holdings plc
Core business involves developing gene therapies using AAV vectors and a riboswitch platform; MeiraGTx is a clinical-stage biotechnology company focused on genetic medicines.
|
$607.38M |
$7.40
-1.99%
|
|
CRVS
Corvus Pharmaceuticals, Inc.
Lead pipeline includes oncology-focused therapies (soquelitinib) with activity in T-cell lymphomas, aligning with Oncology-focused biotech development.
|
$599.84M |
$8.05
+12.82%
|
|
HYEX
Healthy Extracts Inc.
Exclusive rights to an oral delivery technology for nutritional supplements, a distinctive platform that differentiates the company’s product delivery.
|
$593.59M |
$1.94
|
|
EBS
Emergent BioSolutions Inc.
EBS directly develops and manufactures vaccines and vaccine-derived MCMs (BioThrax, ACAM2000, TEMBEXA) for government/public health programs.
|
$586.33M |
$10.99
+0.41%
|
|
RAPT
RAPT Therapeutics, Inc.
RAPT's pipeline includes oncology-focused assets under Biotech - Oncology (tivumecirnon) and broader oncology immunotherapy focus.
|
$580.48M |
$35.02
+8.79%
|
|
GOSS
Gossamer Bio, Inc.
Inhaled seralutinib represents a drug-delivery platform that concentrates therapy in the lungs to treat pulmonary hypertension, a major differentiator.
|
$573.00M |
$2.52
+3.06%
|
|
DBVT
DBV Technologies S.A.
Viaskin Peanut EPIT patch is a drug-delivery platform; DBV Technologies directly develops and commercializes this patch-based immunotherapy.
|
$569.26M |
$20.74
+10.32%
|
|
DNA
Ginkgo Bioworks Holdings, Inc.
Antibody Discovery Platform reflects the antibody-focused tools and services offered.
|
$565.36M |
$9.56
-0.16%
|
|
ABSI
Absci Corporation
Absci's core platform is an Antibody Discovery Platform combining AI design with high-throughput wet-lab validation (lab-in-the-loop) for de novo antibody generation.
|
$559.21M |
$3.87
+3.34%
|
|
MYGN
Myriad Genetics, Inc.
Companion diagnostics—biomarker-based tests that stratify patients for targeted therapies; aligns with Myriad's genetic tests.
|
$550.82M |
$5.92
-1.99%
|
|
REPL
Replimune Group, Inc.
Replimune is oncology-focused biotech developing oncolytic immunotherapies.
|
$549.51M |
$7.03
-3.77%
|
Showing page 10 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
